SG 9902314-5

**PCT** WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 38/13, 47/00, 47/08, 47/10, 47/14, 47/26, 47/34, 9/00 — A1

(11) International Publication Number: WO 99/20296

(43) International Publication Date: 29 April 1999 (29.04.99)

(21) International Application Number: PCT/US98/22330

(22) International Filing Date: 21 October 1998 (21.10.98)

(30) Priority Data:
08/956,841 23 October 1997 (23.10.97) US

(71) Applicant: SANGSTAT MEDICAL CORPORATION [US/US]; 1505–B Adams Drive, Menlo Park, CA 94025 (US).

(72) Inventors: CHU, Moo, J.; 202 Windhover Drive, Chapel Hill, NC 27514 (US). LEVY, Ralph, E.; 6637 Amber Lane, Pleasanton, CA 94566 (US). POULETTY, Philippe, J.; 3 O'Dell Place, Atherton, CA 94027 (US).

(74) Agents: TRECARTIN, Richard, F. et al.; Flehr, Hohbach, Test, Albritton & Herbert LLP, Suite 3400, 4 Embarcadero Center, San Francisco, CA 94111–4187 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published**
*With international search report.*

(54) Title: ORAL CYCLOSPORIN FORMULATIONS

(57) Abstract

Improved oral cyclosporin formulations which have high bioavailability and are capable of administration in both liquid and hard capsule form are provided. In the subject formulations, cyclosporin is delivered in an orally acceptable vehicle comprising at least one alkanol solvent of from 2 to 3 carbon atoms in combination with at least one non–ionic surfactant. The subject formulations may further comprise at least one co-solvent, where cosolvents of interest include fatty acids and diols. The subject formulations find use in immuno–suppressive therapy.

